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Spinal cord injury (SCI) is a devastating medical condition 
without a cure. Reestablishment of neuronal connections 
after spinal cord injury is the “holy grail” of SCI research. 
However, grafting exogenous cells, including neural stem 
cells and a variety of adult somatic cells, has had very lim-
ited success [1]. Two back-to-back papers published in the 
Proceedings of National Academy of Sciences USA by the 
Li and Sun groups have provided exciting information by 
bringing activated endogenous neurogenesis into play, using 
a biomaterial called chitosan that was loaded with neu-
rotrophic factor 3 (NT3) to achieve slow release of the 
trophic factor. Moreover, these papers have provided a 
mechanistic insight using analyses of gene expression and 
neuronal function.   
We now know that after SCI, the development of a 
non-permissive microenvironment by a combination of sev-
erance of axons and vascular structure, edema, infiltration 
of immune cells and progressive gliosis and scar formation 
creates a barrier for neuronal regeneration. It has been sug-
gested that a neural stem/progenitor cells (NSCs) niche that 
resides in the central nervous system (CNS) can potentially 
be activated for neural regeneration, but little progress has 
been made in exploiting this process therapeutically in SCI.  
In the first study by Yang et al. [2], the authors applied 
an innovative chitosan-NT3 biomaterial which not only 
bridged the transected spinal cord, but also released NT3 
slowly to provide a favorable microenvironment for NSC 
activation and migration. They transected and extracted a 5 
mm spinal cord segment at T7/8, filled the gap immediately 
after the injury with NT3-chitosan, and followed up the re-
covery at different stages after the injury (from 30 days up 
to 1 year). The researchers checked tissue recovery in the 
lesion area as well as in regions that were rostral (R) or 
caudal (C) to the lesion. In addition, using Basso, Beattie 
and Bresnahan (BBB) post injury locomotor analyses mon-
itored functional recovery. The authors observed that BBB 
scores of animals in the NT3-chitosan group were much 
higher than those of the control groups up to 52 weeks (1 
year) post injury, and that tissue repair was a slow process, 
with partial successful functional recovery dependent on the 
gradual release of NT3 by chitosan over time. To further 
test whether recovery of locomotion was due to the tissue 
regeneration, the authors resected the nerve terminals in the 
same lesion area and replaced the NT3-chitosan with a plas-
tic diaphragm, which completely abolished restoration of 
locomotor behavior, and thus excluded the possibility that 
an intrinsic compensatory mechanism rescued the lesion. 
The anatomical and behavioral recovery was associated 
with functional synapse formation between the regenerated 
neurons within the chitosan conduit (the injury site). Next, 
the authors provided evidence that spontaneous activation 
of endogenous NSCs by injury and NT3 contributed to the 
generation of neurons. To further explore this hypothesis, 
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the authors blocked NSC proliferation pharmacologically, 
and observed a 30% decrease in the amplitude of soma-
tosensory evoked potentials (SEPs) and motor evoked po-
tentials (MEPs) in the treated group, suggesting a consistent 
contribution of newly generated neurons to locomotor func-
tional recovery. These experiments suggest that the estab-
lishment of a permissive microenvironment may be im-
portant for neuronal tissue regeneration.  
In an accompanying paper by Duan et al. [3] from the 
same group, the authors used genomic analysis to probe the 
mechanism underlying the activation of endogenous NSCs, 
and to search for possible prohibitive factors that could 
hamper regeneration of neurons after SCI. Using an ingen-
uous analytical method called the Weighted Gene Coex-
pression Analysis (WGCNA), the authors found a gene ex-
pression pattern which suggested that the NT-3 chitosan 
bio-tube may dampen inflammatory immune processes [3], 
enhance formation of blood vessels, and promote de novo 
neurogenesis. WGCNA analysis involves identification of 
gene modules that are representative of pathological events, 
and potentially allows definition of diagnostic hallmarks 
and targets for future therapeutic interventions.  
In recent years cell-based therapies have tried to utilize 
pluripotent stem cells and adult-derived stem cells of dif-
ferent origin or more mature cells such as mesenchymal 
stem cells, olfactory ensheathing cells, and Schwann cells 
[4]. Nonetheless, in the treatment of SCI, cell transplanta-
tion is often hampered by poor cell survival. To overcome 
this drawback, investigators have grafted cells in combina-
tion with biomaterials that are meant to physically mimic 
CNS tissue and to foster a permissive environment for cell 
survival, growth, and differentiation. However, the risk of 
immune rejection or tumor development remains a major 
drawback of this approach [5]. Therefore mobilization of an 
endogenous pool of NSCs may be a more promising ap-
proach, but currently no studies have produced a successful 
protocol to achieve this, and a variety of experimental data 
led to questions about the molecular mechanisms underly-
ing functional recovery after SCI. One of the main reasons 
for this heterogeneity resides in the lack of a temporal anal-
ysis aimed at determining a pipeline of pathological hall- 
marks from SCI to recovery. The two recent papers ad-
dressed these critical hurdles in SCI treatment.  
However, several critical questions still require clarifica-
tion. For example, what are the cell types regenerated in the 
lesion site, what is their composition and, importantly, how 
do non-neuronal cells like astrocytes potentially contribute 
to the recovery [6]? Moreover, what is the relationship be-
tween the intact neural structure and the newly regenerated 
cells, including the synaptic connections of descending in-
puts, intraspinal circuits, or circuits formed within the new 
cells?  
As a whole, the two studies by the Li and Sun groups 
report promising results suggesting that the slow release of 
a neurotrophin (NT3) by a biomaterial (chitosan) can be 
effective in promoting physiological repair processes in SCI 
and in dampening the deleterious effects secondary to   
the progression of chronic neuro-inflammation [2]. Moreo-
ver, using WGCNA, the authors established a gene- module 
analysis approach corresponding to various pathological 
events at different times after SCI, which provides mecha-
nistic clues to potentially more effective treatments for  
SCI [3].  
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